PubMed Health⌕ Search

Biomedical subjects

H L Roth

Publications and source records attributed to H L Roth.

10 recordsLinked to original sources
PubMed1988

Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis.

Data from 104 subjects with tinea cruris or tinea corporis were evaluated in this double-blind, randomized study. The subjects applied naftifine cream 1% or econazole nitrate cream 1% to affected areas twice daily for 4 weeks. After 1 week of treatment naftifine had an overall cure rate of 19% compared with 4% for econazole (p = 0.03). A difference in favor of naftifine, although not statistically significant after the first week, persisted throughout treatment. Two weeks after the end of treatment both medications had overall cure rates of approximately 80%. Three percent of the naftifine-treated subjects had side effects compared with 13% of the econazole-treated subjects. In two subjects using econazole, the side effects were severe enough to warrant discontinuation of treatment.

Adolescent↗
PubMed1988

Group psychotherapy as an aid in the medical treatment of eczema.

The ongoing management of severe adult eczema is often difficult and problematic for both patient and doctor. A group of ten adult eczema patients were given group psychotherapy as a supplement to their regular medical regimen. Five target symptoms were rated on a biweekly basis first to establish individual baselines of disease course and later to measure treatment effect. The psychologic treatment combined behavioral and cognitive interventions with relaxation training. Patients used multiple self-rating sheets to provide feedback with the goal of increasing their skills in the management of scratching behaviors. At the end of treatment all ten patients showed significant reduction in targeted symptoms.

Behavior Therapy↗
PubMed1986

Antimigraine drug interactions with 5-hydroxytryptamine1A receptors.

The interactions of four antimigraine drugs with 5-hydroxytryptamine1A and beta-adrenergic receptors were analyzed in rat brain membranes. Methysergide, cyproheptadine, (-)propranolol, and pizotifen display similar affinities (IC50 values, 83 to 280 nM) for 5-hydroxytryptamine1A receptors labeled by [3H]8-hydroxy-N,N-dipropyl-2-aminotetralin. Cyproheptadine, pizotifen, and methysergide are essentially inactive at beta-adrenergic receptors labeled by [3H]dihydroalprenolol (IC50 values, 8,700 to 87,000 nM). By contrast, (-)propranolol is an extremely potent beta-adrenergic agent (IC50, 3 nM). These data indicate that the 5-hydroxytryptamine1A receptor is a common site of action for (-)propranolol and other antimigraine agents.

8-Hydroxy-2-(di-n-propylamino)tetralin↗
PubMed1978

Hydrocortisone valerate. Double-blind comparison with two other topical steroids.

Hydrocortisone valerate cream (0.2 percent) was evaluated in three controlled clinical trials involving a total of sixty-eight patients with atopic dermatitis. This new nonfluorinated steroid was found to be as effective as the fluorinated beta-methasone valerate cream (0.1 percent) and significantly more effective than hydrocortisone cream (0.1 percent) and the placebo cream base. All studies were double-blind, paired comparisons, utilizing application of the medications three times a day for up to four weeks or until clearing occurred.

Administration, Topical↗
PubMedDate not supplied

Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis.

Studies were conducted to assess the bioequivalence of a new antimycotic formulation, ciclopirox olamine lotion 1%, to an established compound, ciclopirox olamine cream 1%. Results of in vitro studies, using skin samples from human cadavers and domestic pigs, demonstrated that the two formulations equally penetrate all layers of the stratum corneum and inhibit the growth of Trichophyton mentagrophytes and Candida albicans. In vivo studies in guinea pigs and in human volunteers demonstrated the comparable therapeutic efficacy of the lotion and the cream in experimental trichophytosis. In addition, a multicenter, double-blind clinical trial was undertaken to compare ciclopirox olamine lotion 1% with the vehicle alone in the treatment of patients with tinea pedis. Patients with plantar, interdigital, or vesicular tinea pedis were enrolled in the studies. Patients were treated for 28 days. Clinical and mycological responses were determined during treatment and two weeks posttreatment. Ciclopirox olamine lotion 1% was found to be significantly more effective than its vehicle in the treatment of patients with common tinea pedis. Minor localized side effects (pruritus, burning sensation) were reported in 2% of 89 patients treated with ciclopirox olamine lotion 1%. The results demonstrate the bioequivalence of ciclopirox olamine lotion 1% and ciclopirox olamine cream 1% and confirm the clinical effectiveness and safety of the lotion in the treatment of tinea pedis, a generally recalcitrant fungal infection. It is concluded that ciclopirox olamine lotion 1% can be used as an alternative to ciclopirox olamine cream 1% for treatment of tinea pedis, tinea versicolor, tinea cruris, tinea corporis, and cutaneous candidiasis when the convenience and/or cosmetic elegance of a lotion is desired.

Administration, Topical↗